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OBJECTIVES The aim of this research was to compare relative efficacy of different statin regimens in
achieving the dual goals of low-density lipoprotein cholesterol (LDL-C) and C-reactive
protein (CRP) reduction.
BACKGROUND While secondary prevention guidelines for statin therapy suggest lowering LDL-C levels70
mg/dl, we have recently shown that clinical outcomes are improved when CRP levels are also
lowered 2 mg/l.
METHODS We addressed the relative efficacy of pravastatin 40 mg and atorvastatin 80 mg daily to reduce
LDL-C and CRP among 3,745 acute coronary syndrome patients.
RESULTS A total of 1,018 participants (27.1%) achieved the dual goals of LDL-C70 mg/dl and CRP
2 mg/l. After adjustment for age, gender, smoking, diabetes, hypertension, obesity, and
HDL-C, these individuals had a 28% lower risk of recurrent myocardial infarction or vascular
death (relative risk 0.72; 95% confidence interval 0.52 to 0.99). Of those who achieved dual
goals, 80.6% received atorvastatin 80 mg, while 19.4% received pravastatin 40 mg (p 
0.001). Only 11% allocated pravastatin and 44% allocated atorvastatin achieved the goals of
LDL-C70 mg/dl and CRP2 mg/l, and only 5.8% allocated pravastatin 40 mg and 26.1%
allocated atorvastatin 80 mg reached the even lower goals of LDL-C 70 mg/dl and CRP
1 mg/l. The correlation coefficient for CRP measured at 30 days and at end of study was
0.61 (p  0.001), a value almost identical to that for LDL-C over the same follow-up period
(r  0.62, p  0.001).
CONCLUSIONS While atorvastatin 80 mg was superior to pravastatin 40 mg in terms of achieving the dual
goals of aggressive LDL-C and CRP reduction, neither agent brought the majority of
patients below thresholds needed to maximize patient benefit. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.0801644–8) © 2005 by the American College of Cardiology Foundation
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(urrent guidelines for statin therapy provide the option to
educe low-density lipoprotein cholesterol (LDL-C) 70
g/dl among very high-risk patients with a history of
yocardial infarction or acute coronary syndrome (1).
owever, in addition to lowering LDL-C, statin therapy
lso lowers high-sensitivity C-reactive protein (hsCRP) in a
argely lipid-independent manner (2–5), and it has been
emonstrated that the relative efficacy of statins appears
reater among those with elevated hsCRP levels (4,6).
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ospital, Boston, Massachusetts. The PROVE IT-TIMI 22 trial was supported by
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co-inventor on patents held by the Brigham and Women’s Hospital that relate to
he use of inflammatory biomarkers in cardiovascular disease.4
Manuscript received January 23, 2005, revised manuscript received February 15,
005, accepted February 22, 2005.We recently showed in the Pravastatin or Atorvastatin
valuation and Infection (PROVE-IT) Thrombolysis In
yocardial Infarction (TIMI)-22 trial that the lowest rates
f recurrent myocardial infarction or cardiovascular death
mong statin-treated patients occur among those who not
nly achieve LDL-C goals70 mg/dl, but who also achieve
sCRP goals 2 mg/l (7). On this basis, physicians pro-
iding optimized statin care may elect to measure and
onitor hsCRP levels in a manner analogous to that of
DL-C. To date, however, there are no comparative data
escribing the relative ability of different statin regimens to
chieve the “dual goals” of aggressive LDL-C and hsCRP
eduction.
ETHODS
he PROVE-IT TIMI-22 study was a randomized 2 by 2
actorial design trial evaluating the effects of intensive
atorvastatin 80 mg oral daily) versus moderate (pravastatin
0 mg oral daily) statin therapy and of gatifloxicin versus
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mong 4,162 patients with acute coronary syndrome (8).
Details of the overall PROVE-IT TIMI-22 study design
nd of the prespecified C-reactive protein (CRP) protocol
7,8) have been presented previously. In brief, as part of the
tudy design, plasma samples were sought at randomization
nd at day 30, 4 months, and the end of study. The level of
DL-C and hsCRP achieved after initiation of statin
herapy was defined as the level at 30 days, a period of time
dequate for the effect of statin therapy to be observed for
oth LDL-C and hsCRP, and when the residual effects of
schemia on both of these parameters would be overcome. A
otal of 3,745 participants (90%) were alive and free of
ecurrent events at day 30 and underwent evaluation for
oth LDL-C and hsCRP. All laboratory measures were
ade in a core facility, and a validated assay was used for
sCRP.
The relative efficacy of pravastatin 40 mg and atorvastatin
0 mg in lowering LDL-C and hsCRP was evaluated in
everal stages. First, Spearman correlation coefficients were
sed to evaluate the relationship between achieved LDL-C
t 30 days and achieved hsCRP at 30 days for each statin.
econd, we calculated the number of study participants who
id and did not achieve the dual goals of LDL-C 70
g/dl and hsCRP 2 mg/l, both for the total study cohort,
nd in separate strata according to randomized drug assign-
ent. The relative proportions of study participants on each
gent were then calculated and compared using chi-square
nalysis. Age-adjusted incidence rates for recurrent myocar-
ial infarction or cardiovascular death were computed for
hose who did and did not achieve the dual goals cited
bove, and Cox proportional hazards models were used to
etermine relative risks of these recurrent events in age-
Abbreviations and Acronyms
CRP  C-reactive protein
HDL-C  high-density lipoprotein cholesterol
hsCRP  high-sensitivity C-reactive protein
LDL-C  low-density lipoprotein cholesterol
PROVE-IT  Pravastatin or Atorvastatin Evaluation
and Infection trial
TIMI  Thrombolysis In Myocardial Infarction
able 1. Proportion of Patients in the PROVE-IT TIMI-22 Tri
70 mg/dl and C-Reactive Protein 2 mg/l in the Total Cohor
Patient Group
Total Cohort
N
(%)
Event
Rate*
RRage
(95% CI)
RRfully
(95% CI)
N
(%)
ual goals not achieved 2,727
(72.8)
3.7 ref ref 1,051
(56.1
ual goals achieved 1,018
(27.2)
2.4 0.65
(0.47–0.89)
0.71
(0.52–0.98)
821
(43.9
his table also shows incidence rates and relative risks of recurrent myocardial infarct
referent group). *Rate is age-adjusted per 100 person years. RRage is the age-adjusted
iabetes, hypertension, and body mass index.
CI  confidence interval; ref  referent group.djusted analyses, fully adjusted analyses, and according to
ravastatin or atorvastatin allocation. Incidence rates were
ge-adjusted by the method of direct standardization using
0-year age categories. Similar analyses were performed
ddressing the proportion of participants on each random-
zed agent who not only achieved LDL-C 70 mg/dl, but
ho also achieved hsCRP levels 1.5, 1.0, and 0.5
g/l. Comparisons were also made between hsCRP and
DL values obtained at 30 days to those obtained at 4
onths and at end of study. All p values are two-tailed; all
onfidence intervals computed at the 95% level, and all
utcomes adjusted for gatifloxicin therapy, an agent that had
o significant effects on hsCRP levels in this population.
ESULTS
oth pravastatin 40 mg and atorvastatin 80 mg reduced
DL-C and hsCRP levels after 30 days of therapy. How-
ver, for both agents, the correlation between achieved
DL-C and achieved hsCRP at 30 days was minimal such
hat the magnitude of LDL-C reduction could not be used
o gauge hsCRP reduction for individual patients (r  0.04
or pravastatin, r  0.15 for atorvastatin).
Of the 3,745 acute coronary syndrome patients random-
zed in the PROVE-IT TIMI-22 trial who were alive and
ree of recurrent events at 30 days, 1,018 (27%) achieved the
ual goals of LDL-C70 mg/dl and hsCRP2 mg/l after
nitiation of statin therapy (Table 1). Compared to those
ho did not achieve both target goals, those who did had
ignificantly improved event-free survival in terms of recur-
ent myocardial infarction or coronary death during the
ubsequent 2.5 years of follow-up (2.4 vs. 3.7 per 100 person
ears, p  0.007) (Fig. 1). Overall, those who achieved the
ual goals had a 35% lower risk of recurrent events (age-
djusted relative risk  0.65, 95% confidence interval 0.47
o 0.89, p  0.007). After full adjustment of age, gender,
moking status, diabetes, hypertension, and body mass
ndex, those who achieved dual goals had a 29% lower risk
f recurrent cardiovascular events (fully adjusted relative risk
0.71, 95% confidence interval 0.52 to 0.98, p 0.04). As
lso shown in Table 1, the magnitude of relative risk
eduction comparing those who did and did not achieve
ual goals was virtually identical in analyses stratified by
aching Dual Goals of Low-Density Lipoprotein Cholesterol
According to Statin Allocation
Atorvastatin Pravastatin
ent
te*
RRage
(95% CI)
RRfully
(95% CI)
N
(%)
Event
Rate*
RRage
(95% CI)
RRfully
(95% CI)
.4 ref ref 1,676
(89.5)
3.9 ref ref
.3 0.69
(0.46–1.02)
0.73
(0.48–1.10)
197
(10.5)
2.4 0.64
(0.33–1.21)
0.71
(0.37–1.36)
cardiovascular death comparing those who achieved dual goals to those who did not
ve risk while RRfully is the relative risk fully adjusted for age, gender, smoking status,al Re
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Differential Efficacy of Statins on LDL and CRP May 17, 2005:1644–8tatin allocation (fully adjusted relative risk  0.73 in the
torvastatin group, 0.71 in the pravastatin group, p value
etween groups  NS). In post-hoc analyses limited to the
nd point of cardiovascular death (n  38), those who
chieved the dual goals had, if anything, an even larger
eduction in risk (incidence rates 0.3 vs. 0.6 cardiovascular
eaths per 100 person-years for those who did and did not
chieve dual goals, relative risk  0.50, 95% confidence
nterval 0.21 to 1.19).
The relative efficacy of pravastatin 40 mg and atorvastatin
0 mg in achieving LDL-C levels 70 mg/dl and hsCRP
evels 2 mg/l are presented in Table 2. Of the 1,018
articipants who achieved these dual goals, 821 (80.6%) had
een randomly allocated to atorvastatin 80 mg while 197
19.4%) had been randomly allocated to pravastatin 40 mg,
highly significant difference (p  0.001). However, as also
hown in Table 2, neither agent brought the majority of
atients treated below thresholds needed to maximize pa-
ient benefit. Specifically, only 11% of those allocated
ravastatin 40 mg and 44% of those allocated atorvastatin
igure 1. Cumulative incidence of recurrent myocardial infarction or coron
chieve the dual goals of low-density lipoprotein cholesterol (LDL-C) 7
ncidence for those who achieved LDL-C 70 and the even lower hsCR
ABLE 2. Relative Efficacy of Pravastatin 40 mg and Atorvastatin
2 mg/l in the PROVE-IT TIMI-22 Trial
Patient Group
Total Cohort
(%Pravastatin/%Atorv
DL-C 70 mg/dl, CRP 2 mg/l 75.8/24.2
DL-C 70 mg/dl, CRP 2 mg/l 71.6/28.4
DL-C 70 mg/dl, CRP 2 mg/l 28.2/71.8
DL-C 70 mg/dl, CRP 2 mg/l 19.4/80.6
ata are shown as the proportion of patients on pravastatin or atorvastatin within eac
chieving respective LDL-C and CRP goals.
CRP  C-reactive protein; LDL-C  low-density lipoprotein cholesterol.0 mg achieved the dual goals of LDL-C 70 mg/dl and
sCRP 2 mg/l.
As would be anticipated given known differential effects
n high-density lipoprotein cholesterol (HDL-C), those
llocated to pravastatin 40 mg had higher HDL-C levels
fter 30 days of therapy than those allocated to atorvastatin
41.0 vs. 38.2 mg/dl, p  0.01). Because those allocated to
torvastatin were, on average, more likely to achieve dual
oals, it follows that those who achieved dual goals also had
ower HDL-C levels (39.4 vs. 41.4 mg/dl, p  0.001).
owever, even after further additional adjustment for
DL-C, those who achieved dual goals still had a 28%
ower risk of recurrent cardiovascular events (fully adjusted
elative risk with additional HDL-C control  0.72, 95%
onfidence interval 0.52 to 0.99, p  0.04).
Figure 2 presents the proportion of patients allocated to
ither atorvastatin 80 mg or pravastatin 40 mg who not only
chieved an LDL-C 70 mg/dl, but who also achieved the
sCRP goals of 2.0, 1.5, 1.0, and 0.5 mg/l; data are
hown after 30 days of therapy (Fig. 2, top panel), 4 months
eath in the PROVE-IT TIMI-22 trial among those who did and did not
dl and high-sensitivity C-reactive protein (hsCRP) 2 mg/l. Cumulative
l of 1 mg/l is also shown (dotted line).
g in Achieving LDL-C Levels 70 mg/l and CRP Levels
n)
Pravastatin 40 mg
N (%)
Atorvastatin 80 mg
N (%)
823 (43.9) 263 (14.0)
644 (34.4) 255 (13.6)
209 (11.2) 533 (28.5)
197 (10.5) 821 (43.9)
L- C/CRP category (total cohort) and as the number (N) and percent on each agentary d80 m
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May 17, 2005:1644–8 Differential Efficacy of Statins on LDL and CRPf therapy (Fig. 2, middle panel), and at end of study (Fig.
, bottom panel). As shown in the initial 30-day data, only
.8% of those allocated pravastatin 40 mg achieved LDL-C
evels 70 mg/dl and hsCRP levels 1 mg/l, whereas these
ven lower goals were achieved by 26.1% of those allocated
torvastatin 80 mg. This subgroup with achieved hsCRP
evels 1 mg/l also had lower recurrent event rates com-
ared even to those who achieved the dual goals of LDL-C
70 mg/dl and hsCRP 2 mg/l (Fig. 1, dotted line). Only
.2% of those on pravastatin 40 mg and 11.5% on atorva-
tatin 80 mg achieved the very lowest goals of LDL-C 70
g/dl and hsCRP 0.5 mg/l (all p values 0.01). As also
hown in Figure 2, the relative differences between prava-
tatin and atorvastatin persisted after four months of therapy
nd at the end of study.
Levels of hsCRP measured at 30 days were highly
redictive of levels measured after four months and at the
igure 2. Proportion of patients treated with atorvastatin 80 mg (black b
holesterol (LDL-C) levels70 mg/dl and high-sensitivity C-reactive prot
aken after 30 days of therapy, after 4 months of therapy, and at the endnd of study for both the pravastatin-allocated participants r values  0.65 and 0.60, respectively) and for the
torvastatin-allocated participants (r values 0.65 and 0.60,
espectively) (all p values 0.001). Consistent with prior
ata, the stability of hsCRP levels over long periods of
ollow-up were comparable to that of LDL-C. In these
ata, the correlation between hsCRP levels measured at 30
ays for the total study group and hsCRP levels measured at
he end of study was 0.61 (p  0.001), a magnitude of
orrelation almost identical to that of LDL-C levels mea-
ured at both time points for the same population (r 0.62,
 0.001).
ISCUSSION
n this analysis of the PROVE-IT TIMI-22 trial, acute
oronary syndrome patients treated with statin therapy who
chieved the dual goals of LDL-C 70 mg/dl and hsCRP
nd pravastatin 40 mg (white bars) who achieved low-density lipoprotein
sCRP) levels2,1.5,1, and0.5 mg/l. Data are shown for measures
dy.ars) a
ein (h2 mg/l had a 28% lower risk of recurrent myocardial
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Differential Efficacy of Statins on LDL and CRP May 17, 2005:1644–8nfarction or cardiovascular death after adjustment for age,
ender, smoking, diabetes, hypertension, body mass index,
nd HDL-C. Moreover, we demonstrate here that an
ggressive lipid-lowering regimen of atorvastatin 80 mg
aily is superior to a moderate regimen of pravastatin 40 mg
aily in terms of the proportion of individuals treated who
ltimately will achieve LDL-C 70 mg/dl and hsCRP 2
g/l. Importantly, we also demonstrate that neither regi-
en brought the majority of treated individuals into the
ange needed for the best long-term event-free survival. For
xample, while achieving the even lower hsCRP goal of 1
g/l along with an LDL-C 70 mg/dl appears to provide
urther survival benefit, this very low level of hsCRP was
chieved by only 5.8% of those allocated pravastatin 40 mg
nd only 26.1% of those allocated atorvastatin 80 mg.
inally, our data demonstrate that the long-term stability of
sCRP levels after reduction with statin therapy is of almost
dentical magnitude to that of LDL-C.
We believe these data on the relative efficacy of different
tatin regimens in achieving both hsCRP and LDL-C goals
re clinically relevant for several reasons. First, these data
mphasize the importance of continued aggressive programs
f weight loss, dietary control, exercise, and smoking ces-
ation among post-acute coronary syndrome patients, in
ddition to aggressive statin therapy. Weight loss, exercise,
nd smoking cessation consistently lead to reductions in
RP that are at least as large in magnitude as those achieved
ith pharmacologic intervention, and it is these core life-
tyle issues that must be emphasized as being of crucial
mportance to long-term secondary prevention (9).
Second, while atorvastatin 80 mg was more effective than
ravastatin 40 mg in achieving the “dual goals” of LDL-C and
sCRP reduction, the fact that the majority of those taking the
ore aggressive treatment still did not meet these goals
mphasizes the need to continue evaluating agents that might
urther lower hsCRP levels. From this perspective, our obser-
ations may help to explain results from the A to Z trial in
hich no significant difference in outcome was observed early
n the trial despite large differences in achieved LDL-C, yet
vidence of a benefit was observed later when differences in
chieved hsCRP emerged between study groups (10). Our data
lso raise important clinical questions about alternative lipid
eduction approaches such as ezetimibe, an agent that on its
wn does not lower hsCRP, but that in combination with
tatin therapy appears to augment reduction of both LDL-C
nd hsCRP (11). Similarly, these data raise intriguing hypoth-
ses regarding the potential additive benefits of fibrates, gem-
brozil, and TZD therapy, all of which lower hsCRP levels
12,13). Our observations also support trials of agents that
pecifically block CRP itself, either using antisense drug
echnologies, enzyme blockade strategies, or anti-CRP anti-
ody approaches. Such trials will be critical in evaluating the
echanistic possibility that CRP is more than a marker of
isease, but also potentially is a direct participant in the
therogenic process.
The PROVE-IT TIMI-22 trial was limited to those withcute coronary syndromes and, thus, represents a secondary
revention population in which all participants had a clear
ndication for statin therapy. As such, these data addition-
lly support continued enrollment into the JUPITER trial,
n ongoing randomized, placebo-controlled study of rosu-
astatin 20 mg versus placebo in the primary prevention of
ardiovascular disease among apparently healthy individuals
ho do not qualify for statin therapy because their LDL-C
evels are 130 mg/dl, yet who are at increased risk due to
levated CRP levels (14).
eprint requests and correspondence: Dr. Paul M. Ridker,
enter for Cardiovascular Disease Prevention, Brigham and
omen’s Hospital, 900 Commonwealth Avenue East, Boston,
assachusetts 02215. E-mail: pridker@partners.org.
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